TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC increased its stake in TG Therapeutics by 42.4% during the first quarter, owning 40,547 shares valued at approximately $1.6 million.
• Goldman Sachs has raised TG Therapeutics to a "hold" rating with a price target of $37.00, while analysts currently rate the stock as a "Moderate Buy" with an average target price of $46.25.
• TG Therapeutics reported a 92.1% year-over-year increase in revenue for the latest quarter, totaling $141.15 million, though it missed the earnings expectations with an EPS of $0.17.

Natixis Advisors LLC increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 42.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,547 shares of the biopharmaceutical company's stock after acquiring an additional 12,065 shares during the quarter. Natixis Advisors LLC's holdings in TG Therapeutics were worth $1,599,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CWM LLC boosted its position in shares of TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after acquiring an additional 290 shares during the last quarter. Golden State Wealth Management LLC lifted its position in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares during the last quarter. Xponance Inc. lifted its position in TG Therapeutics by 5.3% in the first quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock valued at $428,000 after buying an additional 543 shares during the last quarter. Finally, Choreo LLC lifted its position in TG Therapeutics by 7.6% in the first quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock valued at $337,000 after buying an additional 602 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insider Activity

In related news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 10.64% of the company's stock.

TG Therapeutics Stock Down 1.2%

NASDAQ:TGTX traded down $0.32 during mid-day trading on Monday, hitting $26.39. The stock had a trading volume of 4,561,601 shares, compared to its average volume of 2,522,735. The stock has a 50-day simple moving average of $36.10 and a two-hundred day simple moving average of $36.05. The company has a market capitalization of $4.19 billion, a PE ratio of 71.32 and a beta of 1.95. TG Therapeutics, Inc. has a twelve month low of $20.05 and a twelve month high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 27.83% and a net margin of 13.31%. The company had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same period in the previous year, the business posted $0.04 EPS. The firm's revenue for the quarter was up 92.1% compared to the same quarter last year. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.